A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of oral administration of probiotic LKM512 and arginine on function of vascular endothelium in individuals with pre-metabolic syndrome

A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of oral administration of probiotic LKM512 and arginine on function of vascular endothelium in individuals with pre-metabolic syndrome - Effects of probiotic LKM512 and arginine on function of vascular endothelium

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015352

Enrollment

Registered

2014-10-07

Start date

2014-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pre-metabolic syndrome

Interventions

The volunteer were given an 8-week treatment with oral administration of bifidobacteria LKM512 powder (6 billion bacterial cells/stick) and 3 arginine tablets (100mg/tablet) two times per day. The vo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients whose BMl is more than 25.0

Exclusion criteria

Exclusion criteria: 1. Outpatients whose BMl is more than 25.0 2. Subjects who take a medicine for dyslipidemia treatment 3. Serious subjects who have complications with cardiac disease, hepatic disease,and/or renal disease 4. Subjects who had serious gastrointestinal disease in the past 5. Subjects who take hypotensive medicines 6. Subjects who have serious constipation 7. Subjects who was enrolled in other trails within one month 8. Inappropriate cases evaluated by doctors

Design outcomes

Primary

Measure	Time frame
RH-PAT(Endo-PAT)	—

Countries

Japan

Contacts

Public ContactSatoshi Sakurai

imeQ CO. Ltd. CRO division

s-sakurai@imeq.co.jp03-6279-3591

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026